Evaluating the impact of drug candidates on cell proliferation and viability is essential to the success of any drug-discovery or drug-development campaign. Oncology-targeted therapeutics are generally designed to inhibit cancer cell proliferation and viability.
While straightforward cell proliferation assays may reveal inhibitory activity of therapeutics, overall cell health is multi-faceted, necessitating a multiplexed approach assessing cell viability, apoptosis, and necrosis to achieve a comprehensive picture of drug activity.
PhenoVista has developed a R2G Cell Health Assay Service, enabling robust, accurate, simultaneous quantitation of cell viability, apoptosis, necrosis, and proliferation using a homogeneous assay workflow with dye-based detection. This approach maximizes data quality by minimizing pipetting steps and eliminating wash steps that could exacerbate loss of dead or dying cells.
